INTRICON PROMOTES DAVID LIEBL TO CHIEF COMMERCIAL AND TECHNOLOGY OFFICER
ARDEN HILLS, Minn. (July 22, 2022) — Intricon, an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable, and body-worn medical devices, has named David Liebl as its first Chief Commercial and Technology Officer (CCO/CTO).
“The new role is essential as we enhance our commercial growth strategy. Dave’s commercial experience makes him an ideal leader for Intricon’s next phase of growth and development,” said Scott Longval, president and chief executive officer of Intricon. “In Dave’s expanded role, he will be responsible for accelerating our innovation roadmap and expanding our customer relationships.”
Mr. Liebl’s career includes more than 25 years of business development, engineering, and product development experience at multiple high technology and medical technology companies. Prior to joining Intricon in August 2021 as vice president of research and development, Mr. Liebl served as the president of Biomerics NLE’s West Operations. Prior to his role at Biomerics, he held several roles at Heraeus Medical Components/NeoMetrics, Inc., including EVP, product and business development, president and chief technology officer, and VP of development, spanning from 2005 to 2019. His career also includes director and vice president level positions at Pearson, Datacard Group, and MedAmicus, Inc. (now part of Integer Holdings).
“Intricon has a strong foundation of core competencies and technologies, which are well positioned to meet the needs of industry trends. Further, our global manufacturing footprint enables us to meet customer cost targets,” said Liebl. “I’m looking forward to pursuing opportunities in high-growth markets by advancing our technology and commercial operations to meet and exceed our customers’ expectations.”
INTRICON NAMES ANNALEE LUTGEN ITS CHIEF FINANCIAL OFFICER
ARDEN HILLS, Minn. (July 22, 2022) — Intricon, an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, has named Annalee Lutgen as its chief financial officer.
“Annalee will play a critical role on the leadership team and as CFO during this new stage of accelerated growth,” said Scott Longval, Intricon President and CEO. “Annalee knows our business and her proven financial experience in the medical device and high-tech industries is a valuable asset as we continue to expand the company.”
Ms. Lutgen joined Intricon in 2010 as Corporate Controller and has since gained increasing responsibility for the accounting and finance functions of the company, most recently as the Director of Finance. Prior to joining Intricon, Ms. Lutgen was a manager with Grant Thornton. She is a Certified Professional Accountant and holds an MBA from St. Cloud State University.
Lutgen will oversee financial operations for Intricon, which has more than 900 employees across three offices and six manufacturing sites. Intricon recently transitioned from being a publicly traded corporation to a private company, owned by private equity firm Altaris, whose portfolio consists of growth companies in the health care industry.
“I’m excited to take the position of CFO during this transformational period of the company,” said Lutgen. “IntriCon has a solid track record and great potential for growth. As a team, we’re committed to further growing the company.”
About Intricon Corporation
Intricon is an international company and joint development manufacturer (“JDM”) of micromedical components, sub-assemblies and final devices. The Company serves as a JDM partner to leading medical device original equipment manufacturers (“OEMs”) by designing, developing, engineering, manufacturing, packaging and distributing micromedical products for high growth medical markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. Intricon has more than 900 employees across four facilities in the US and two facilities in Southeast Asia.
